anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, endocrinology, hormones, pharmacy. SUBSTANCE: invention relates to different parenteral pharmaceutical compositions that have monomeric insulin analog, zinc, protamine and phenolic derivative. Compositions of analog provide prolonged effect. Invention describes also method of preparing the composition insulin analog-protamine. Invention involves also description of method of treatment of diabetics using the complex of insulin and protamine and pharmaceutical composition containing said. EFFECT: development of agents used for treatment of diabetics, prolonged effect of agent. 31 cl, 1 tbl, 13 ex, 3 dwg
FIELD: articles for personal use. ^ SUBSTANCE: invention refers to the cosmetology and is the preliminary wiping agent to aid the anal region cleansing. The agent includes the base substrate and hydrophobic composition for adherence, and the composition against the adherence includes the softening agent, structurising agent, rheology modifier and compounds for the adherence. All the components of the composition are in certain mass ratios. ^ EFFECT: due to the reduction of the faecal material left in the anal refion after the defecation, this invention provides the improvement of the skin cleansing in the anal regions after the defecation. ^ 5 cl
This pilot RCT study is to examine the comparative effectiveness of two decision aids for hip and knee osteoarthritis. The vendors employ different design features (e.g. use of video for patient narratives, interactive values clarification exercise) and the study will examine the relative impact of the different features on decision quality. Eligible subjects will be randomly assigned to receive one of two decision aids before their upcoming clinic visit with a participating provider. Immediately before the visit, participants will complete a short questionnaire about the decision aid. This pilot study will assist with determining the potential difference between these two decision aids on improving knowledge and use of decision aids.
In recent years, prehabilitation has generated high expectations as an innovative preoperative strategy to enhance clinical outcomes following surgery. Several studies have demonstrated that multimodal programs are effective in improving patients' health status and cardiopulmonary reserve, allowing them to undergo surgery in better conditions and, consequently, reducing the incidence of postoperative complications. Most publications describe proof-of-concept studies, and literature about their implementation is more limited. The implementation of these programs requires new resources and significant organizational effort. In this paper, we share our experience implementing a multimodal prehabilitation program as a mainstream service at a tertiary hospital. Although there are still many unknowns regarding the optimal selection of patients, as well as the duration and components of the program, this article describes our journey in this field, aiming to provide insight for teams interested in developing a similar project.
The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
Crutches are the most prescribed ambulatory assistive device and are used for mobility and maintaining weight-bearing restrictions after injury or surgery. However, standard axillary crutches (SACs) can lead to overuse and other injuries and restrict upper limb movement. Hands-free crutches (HFC) do not restrict upper limb movement but their effect on balance control, with or without commonly prescribed walking boots, is poorly understood. The purpose of this study was to compare the effect of crutch type (SACs vs. HFC) and boot use on whole-body angular momentum (RAM), a measure of balance control. Participant's balance confidence, pain, comfort, and device preference were assessed. Seventeen participants were evaluated while walking without a crutch (NONE), with SACs, and with an HFC, and walked with and without a walking boot in each crutch condition. The gait pattern used with SACs resulted in significantly greater limb angular velocity (p < .05), and an 84% increase in RAM (p < .001) as compared to the HFC. There were no differences between the SAC and HFC for balance confidence, pain, or comfort, however most (71.1%) participants preferred the HFCs. These results suggest that individuals can better control angular momentum with the HFCs and thus may be less susceptible to loss of balance.
Among the patients in the task-oriented training group, 12 sessions were given routinely, 3 days a week, for 4 weeks. Task-oriented training consisted of 25 different stations in total, including 9 different gaze stabilization training, 7 balance training, and 9 gait training stations. Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, eye fixed up-down head movements, head and eye opposing movements (right-left/ up-down), saccadic and pursuit eye movements (right-left/ up-down). Balance and gait training included these exercises: rolling on the mat, vertical rotation, spinning on a rotary disc, standing on balance bord, jumping, playing dart, reaching, walking forward, walking with head movements (right-left/ up-down), tandem walking, '8' shape walking, walking by picking something up from the ground, walking over an obstacle, walking on treadmill, climbing and descending stairs.
Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
The invention relates to cosmetic agents which contain, in relation to their total weight, a. a mixture of surfactants, comprising: i. at least one anionic surfactant, ii. at least one amphoteric and/or zwitterionic surfactant, iii. at least one alkyl (oligo)glycoside and iv. at least one non-ionic surfactant that is different from iii., b. 0.1 to 1.5 % by weight xanthan gum and c. 1.0 to 40 % by weight of at least one vegetable oil. Said agents are particularly stable, even under extreme conditions, and exhibit excellent cleaning and conditioning properties.
A recombinant plasmid DNA pVN22, coding for biosynthesis of human leucocyte interferon alpha-I1 has a size of 10.85 k.b.p. and consists of the following elements: EcoRI-Hind III, a fragment of plasmid pAYC37 of the size 9.45 k.b.p., Hind III-EcoRI, a fragment of the size 1.4 k.b.p. consisting of the following elements: a DNA fragment of the size 0.25 k.b.p. with the regulatory region of gene D phage phix174 and with the initial codons of the interferon gene, an interferon gene alpha-I1 of the size 0.5 k.b.p., a segment of human genomic DNA of the size 0.65 k.b.p.; it has the following genetic markers: a gene ApR providing for ampicillin resistance; a gene SmR providing for streptomycin resistance; it contains the following unique sites of restrictases: Hind III-O; EcoR 1-1.4 k.b.p., Bam H1-10.82 k.b.p. A strain Pseudomonas sp. 31(pVN22), a producer of human leucocyte interferon alpha-I1, containing a recombinant plasmid DNA pVN22, is obtained by the genetic engineering technique by means of introducing said plasmid into the bacterium strain Pseudomonas.
The invention provides a quinoa extract composition, which comprises quinoa total saponins and quinoa total polysaccharides in a weight ratio of 1:10 to 10: 1. The invention also provides a method for preparing the quinoa extract composition. The invention also provides a pharmaceutical composition containing the quinoa extract composition. The invention also provides application of the quinoa extract composition in preparation of a medicament for treating chemotherapy-related diarrhea. The invention also provides a pharmaceutical composition containing the quinoa extract and an anti-tumor drug, and application of the pharmaceutical composition in preparing drugs for treating tumors. The quinoa extract composition provided by the invention has the advantages of being derived from food, good in effect, low in toxicity, low in price and easy to popularize, and can be used for relieving chemotherapy-related diarrhea of cancer patients.
An intervention in this study includes randomization of patients with an infected nonunion to standard of care PO (oral) antibiotics for up to 6 weeks post hospitalization. No medications will be provided by the study. Study participants will be prescribed their oral antibiotics by their treating physician and the specific type will depend on their infection diagnosis. Medications will be obtained using health insurance and/or resources available at the treating facility therefore the mode of antibiotics utilized as standard of care will vary across participating sites. Sites will follow their standard of care delivery for antibiotics and the study will defer to this standard.
PURPOSE OF REVIEW: In this narrative review, we discuss the current evidence related to the role of dietary interventions to prevent and treat type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). We also propose alternative therapeutic strategies other than weight loss in this population, namely, improvements in cardiorespiratory fitness and its determinants.
RECENT FINDINGS: While weight loss has been consistently associated with the prevention of T2DM and improvements in glycemic control in those with established diseases, its role in preventing and treating CVD is less clear. In fact, in this setting, improvements in diet quality have provided greater benefits, suggesting that this might represent an alternative, or an even more effective strategy than energy-restriction. Improvements in diet quality, with and without caloric restriction have been shown to improve CVD risk and to prevent the development of T2DM in individuals at risk; however, with regard to glycemic control in patients with T2DM, any dietary intervention resulting in significant weight loss may produce clinically meaningful benefits. Finally, dietary interventions with and without energy restriction that can improve cardiorespiratory fitness, even in absence of weight loss in patients with obesity, should be encouraged.
Patients will participate in a double blind randomized cross over trial for 6 weeks. Four 2 weeks, half of the type 2 diabetic patients will receive mulberry leaf capsules three times per day with meals (made from Mulberry Zuccarin tablets - New Nordic, 400 mg of mulberry leaf extract per tablet) and half will receive placebo capsules. Following a one week wash out period, the treatments administered to each group will be reversed for the next 2 weeks, and data will continue to be gathered for a final wash out week. Patients will keep a diary of food, exercise, and fasting glucose each morning as well as at least one 2 hour pc glucose each day. Weight, hemoglobin A1C, liver function tests, and renal function tests will be done at baseline and at the end of the 6 weeks. As well, blood pressure will be monitored when the 2 weekly batches of medication are distributed, and at the end of the 6 weeks.
Living cells (56) which produce biologically active factors can be encapsulated within a semipermeable, polymeric membrane by co-extruding an aqueous cell suspension (54) and a polymeric solution (52) through a common port (14) to form a tubular extrudate (12) having a polymeric membrane which encapsulates the cell suspension. For example, the cell suspension and the polymeric solution can be extruded through a common extrusion port having at least two concentric bores (16 and 18), such that the cell suspension is extruded through the inner bore (16) and the polymeric solution is extruded through the outer bore (18). The polymeric solution coagulates to form an outer coating or membrane. As the outer membrane is formed, the ends of the tubular extrudate can be sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links (58). In another embodiment, a cell capsule connected to a tethering filament (59) can be formed.
This study will include 370 children and young people aged 2 to less than 15 years old who are living with HIV and are being treated with anti-HIV medicines for the first time. Participants will be split into two groups, by chance, by a process called "randomisation". One group will continue to receive the anti-HIV medicines already taken according to country-specific routine practice. The second group will change to the new combination of medicine, dolutegravir and lamivudine (with the combination written usually as "DTG/3TC"). Depending on the weight, participants in the second group will be able take the new medicine either as one tablet a day or as a small number of dispersible tablets that are also taken once a day. All children and young people in the study will have regular clinic assessments that are at a similar frequency to the clinic visits that participants would have outside of the study. Blood tests will be performed to check that the medicine is safe and, at some visits, participants and their carers will also be asked to answer some questions on how they feel about taking their medicine. All children and young people will be followed until the last participant who joins the study has been in the study for 96 weeks.
This study will be carried out to determine the effect of motivational interviewing on the level of self-efficacy and addiction in smoking cessation in nursing students. The study was planned as a single-blind randomized controlled experimental study. The population of the research will be composed of students studying in the 1st, 2nd and 3rd years of Ordu University and Giresun University Faculty of Health Sciences Nursing Department and who meet the research criteria, and the sample will be 90 students determined by power analysis. In the study, 30 students from Ordu University Faculty of Health Sciences Nursing Department will be in the experimental group and 30 students in the I. control group. 30 students from Giresun University Faculty of Health Sciences Nursing Department will be in the second control group. Students in the experimental group will be given a motivational interview on quitting smoking for 40-50 minutes on average once a month for 6 months. No intervention will be applied to the students in the control groups during the research process, but a motivational interview will be applied once at the end of the research in terms of ethics. The data of the research will be collected with Personal Information Form, Fagerström Nicotine Addiction Test, Self-Efficacy Scale and Stage of Change Evaluation Form. In the study, repeated measurements will be made in the 1st month, 3rd month and 6th month. Necessary institutional permission and ethics committee approval will be obtained for the research. The analysis of the data will be done by an expert statistician in a computer environment.
PURPOSE:To obtain the title material by adding colloidal silica to a mixture of gypsum and calcium carbonate, thus causing no excessive contraction by heating and keeping high compression strength enough to stand the molding pressure even after being heated. CONSTITUTION:The title material is composed of a thermoplastic resin such as polysulfone and a composition which is prepared by adding 18-40 pts.wt. of colloidal silica (silica sol) to 100 pts.wt. of a mixture containing 30-70 wt% of gypsum and 70-30 wt% of calcium carbonate. The resultant material is free from cracks even when rapidly heated, and free from phase separation caused by vibration whereby a mold for denture with high dimensional stability and strength is obtained. The gypsum is half-hydrated alpha or beta-type, while the calcium carbonate preferably has less than 50 micron particle sizes.
Systems, methods, and apparatuses for debriding a tissue site are described. The system includes a manifold and a cover adapted to form a sealed space over the tissue site for providing negative pressure. The system also includes a debridement tool positioned between the manifold and the tissue site. The debridement tool having a tissue-facing surface and a plurality of holes separated from each other by walls. The walls have transverse surfaces extending between the tissue-facing surface and an opposite surface that form cutting edges. The holes have a perforation shape factor that allows the holes to collapse from a relaxed position to a contracted position in response to the application and removal of negative pressure from the sealed space. The cutting edges debride the tissue site in response to movement between the relaxed position and the contracted position.
<P>PROBLEM TO BE SOLVED: To provide a new method and equipment for delivery of a material to a subject under test.  <P>SOLUTION: This invention includes a method and equipment for delivery of a material. The delivery of a material includes a process of administering non-polymeric hemopoietic cell clot (in which the material is incorporated) to a body under test. The non-polymeric hemopoietic cell clot functions as a delivery vehicle of the material. This invention relates to a new system for application of an active material (for example, a gene delivery vehicle, a cell or a soluble protein) for healing of damaged tissues. This non-polymeric hemopoietic cell clot can be used for the delivery of the material to the subject under test.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention belongs to the technical field of biology, and particularly relates to a composition for regulating PRV infection and application thereof. A composition for modulating PRV infection, said composition comprising a Ku protein. The composition at least comprises one of Ku70 protein or Ku80 protein. Compared with the prior art, the composition for inhibiting PRV infection and the application thereof have the advantages that: and (1) the Ku protein is easy to obtain, free of pathogenicity and high in safety. (2) The Ku protein is safe, harmless and non-infectious during production and operation. (3) The Ku protein has high specificity and high sensitivity for inhibiting PRV infection.
BACKGROUND AND AIMS: Riboflavin transporter deficiency (RTD) is a progressive inherited neuropathy of childhood onset, characterised clinically by pontobulbar palsy, sensory ataxia, sensorineural deafness, muscle weakness, optic atrophy and respiratory failure. A robust and responsive functional outcome measure is essential for future clinical trials of disease-modifying therapies including genetic therapies. The Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS) is a well-validated outcome measure for CMT and related neuropathies, and might have utility for measuring disease progression in individuals with RTD. However, the CMTPedS requires modifications to account for phenotypic differences between children with CMT and RTD. The aim of this study was to develop a functional outcome measure based on the CMTPedS for specific use in individuals with RTD.
METHODS: The CMTPedS data collected over the last 10 years in individuals with RTD attending the Peripheral Neuropathy Management Clinic at the Children's Hospital at Westmead (Sydney, Australia) were reviewed to evaluate each item within the CMTPedS. A literature review of articles published until September 2021 for functional outcome measures generated an item pool for pilot testing. The results of this pilot testing, alongside analysis of existing CMTPedS item scores in the RTD cohort, informed the modification of the CMTPedS.
RESULTS: CMTPedS data were reviewed for eight individuals over the past 10 years. Two items were identified as requiring modification or removal and additional items of proximal strength and function needed to be considered. Six studies were identified in the literature review, and five items were selected for pilot testing. 'Shoulder internal rotation' and the '30-s sit to stand test' were added as proximal measures of strength and function. The composite balance item comprising nine tasks in the CMTPedS showed a ceiling effect and was replaced with the single 'Feet apart on a line eyes open' balance item. 'Pinprick sensation' was removed due to a floor effect.
INTERPRETATION: This study provides preliminary evidence that the Riboflavin Transporter Deficiency Pediatric Scale (RTDPedS) is a functional outcome measure covering strength, upper and lower limb function, balance and mobility for individuals with RTD to assess disease severity and progression in clinical trials and cohort studies.
The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of nasal spray hormone treatment throughout the course. The clinical data of patients at baseline and each visit period were collected, the incidence of adverse events was recorded, and the short-term efficacy and safety of different drug treatment regimens were evaluated.
BACKGROUND: Fruquintinib has received approval for the management of patients with chemotherapy-resistant metastatic colorectal cancer (mCRC). However, combination of fruquintinib with immune checkpoint inhibitors (ICIs) is yet to be extensively studied. This study aims to assess the clinical efficacy, safety, and prognostic indicators of treatment regimen combining fruquintinib with ICIs in mCRC patients.
METHODS: We analyzed data from mCRC patients who were administered fruquintinib either as a monotherapy or in conjunction with ICIs following conventional chemotherapy. Parameters such as the objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and incidence of adverse events were meticulously evaluated. Furthermore, the relationship between blood markers and patient prognosis was examined.
RESULTS: A total of 72 mCRC patients were included in this study, with a median observation period of 48 months, 19 were treated with fruquintinib alone, while 53 received a combination therapy involving fruquintinib and ICIs. The combined therapy group exhibited superior ORR and DCR compared to the fruquintinib monotherapy group. Additionally, significant improvements in OS and PFS were observed in the combined treatment group. The occurrence of adverse events was generally manageable and well-tolerated across both groups, with no significant difference in incidence rates. Notably, albumin levels were identified as a prognostic marker for PFS and OS in the univariate Cox regression analysis.
CONCLUSIONS: The combination of fruquintinib with ICIs demonstrated enhanced clinical efficacy and improved survival outcomes compared to fruquintinib monotherapy in mCRC patients. The safety of the combination regimen was deemed manageable and acceptable.
Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.